CYBN Cybin Inc Quick Ratio

Cybin Inc. (CYBN) research hubs in North America are developing innovative psychedelic delivery methods for mental health therapy. The business currently generates no revenue and relies on external investment, as operating cash flow remains negative. Scaling prospects are based on patents that enable the low-cost synthesis of molecules for global clinic networks. The Quick Ratio stands at 8.21, which is confirmed by the current share price action shown on the charts.

The ratio is calculated as the proportion of the most liquid assets to short-term liabilities, excluding inventory. This metric determines a company's ability to instantaneously settle debts using cash and accounts receivable. For Cybin Inc. (CYBN), this is critical when funding costly CYB003 clinical trials and preparing for FDA approval. By analyzing the trend of the quick ratio, an investor can assess the real financial stability of this biotech firm.